These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32394601)
21. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. Doyle LW; Anderson PJ; Haslam R; Lee KJ; Crowther C; JAMA; 2014 Sep; 312(11):1105-13. PubMed ID: 25226476 [TBL] [Abstract][Full Text] [Related]
22. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study. Poppe T; Thompson B; Boardman JP; Bastin ME; Alsweiler J; Deib G; Harding JE; Crowther CA; EBioMedicine; 2020 Sep; 59():102957. PubMed ID: 32858399 [TBL] [Abstract][Full Text] [Related]
23. A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation. Tan YH; Groom KM Aust N Z J Obstet Gynaecol; 2015 Feb; 55(1):90-3. PubMed ID: 25307153 [TBL] [Abstract][Full Text] [Related]
24. Quality improvement interventions to increase the uptake of magnesium sulphate in preterm deliveries for the prevention of cerebral palsy (PReCePT study): a cluster randomised controlled trial. Edwards HB; Redaniel MT; Sillero-Rejon C; Pithara-McKeown C; Margelyte R; Stone T; Peters TJ; Hollingworth W; McLeod H; Craggs P; Hill EM; Redwood S; Treloar E; Donovan JL; Opmeer BC; Luyt K BJOG; 2024 Feb; 131(3):256-266. PubMed ID: 37691262 [TBL] [Abstract][Full Text] [Related]
25. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit. Ow LL; Kennedy A; McCarthy EA; Walker SP Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):356-60. PubMed ID: 22515404 [TBL] [Abstract][Full Text] [Related]
26. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and 2-year outcomes within a national population-based study (EPIPAGE-2). Lorthe E; Torchin H; Delorme P; Ancel PY; Marchand-Martin L; Foix-L'Hélias L; Benhammou V; Gire C; d'Ercole C; Winer N; Sentilhes L; Subtil D; Goffinet F; Kayem G Am J Obstet Gynecol; 2018 Sep; 219(3):298.e1-298.e14. PubMed ID: 29852153 [TBL] [Abstract][Full Text] [Related]
27. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Crowther CA; Hiller JE; Doyle LW; Haslam RR; JAMA; 2003 Nov; 290(20):2669-76. PubMed ID: 14645308 [TBL] [Abstract][Full Text] [Related]
28. Antenatal magnesium sulfate and neurodevelopmental outcome of preterm infants born to preeclamptic mothers. Bozkurt O; Eras Z; Canpolat FE; Oguz SS; Uras N; Dilmen U J Matern Fetal Neonatal Med; 2016; 29(7):1101-4. PubMed ID: 25893546 [TBL] [Abstract][Full Text] [Related]
29. What we learned about the role of antenatal magnesium sulfate for the prevention of cerebral palsy. Rouse DJ; Hirtz D; Semin Perinatol; 2016 Aug; 40(5):303-6. PubMed ID: 27117179 [TBL] [Abstract][Full Text] [Related]
30. The feasibility of a randomized clinical perinatal trial: maternal magnesium sulfate for the prevention of cerebral palsy. Rouse DJ; Hauth JC; Nelson KG; Goldenberg RL Am J Obstet Gynecol; 1996 Sep; 175(3 Pt 1):701-5. PubMed ID: 8828437 [TBL] [Abstract][Full Text] [Related]
31. Antenatal magnesium sulfate treatment for women at risk of preterm birth is safe and might decrease the risk of cerebral palsy. Huusom LD; Wolf HT BMJ Evid Based Med; 2018 Oct; 23(5):195-196. PubMed ID: 29921710 [No Abstract] [Full Text] [Related]
32. Influence of antenatal magnesium sulfate application on cord blood levels of brain-derived neurotrophic factor in premature infants. Bachnas MA; Mose JC; Effendi JS; Andonotopo W J Perinat Med; 2014 Jan; 42(1):129-34. PubMed ID: 24062546 [TBL] [Abstract][Full Text] [Related]
33. Antenatal magnesium sulphate reduces cerebral palsy after preterm birth, implementation into clinical practice needs to be accelerated globally to benefit preterm babies. Luyt K Cochrane Database Syst Rev; 2024 Sep; 9():ED000168. PubMed ID: 39315530 [No Abstract] [Full Text] [Related]
34. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. Kamyar M; Manuck TA; Stoddard GJ; Varner MW; Clark E BJOG; 2016 Jun; 123(7):1161-6. PubMed ID: 26036660 [TBL] [Abstract][Full Text] [Related]
36. [Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial]. Marret S; Marpeau L; Follet-Bouhamed C; Cambonie G; Astruc D; Delaporte B; Bruel H; Guillois B; Pinquier D; Zupan-Simunek V; Bénichou J; Gynecol Obstet Fertil; 2008 Mar; 36(3):278-88. PubMed ID: 18337147 [TBL] [Abstract][Full Text] [Related]
37. [Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth]. Wolf HT; Henriksen TB; Larsen ML; Pinborg A; Hegaard HK; Brok JS; Huusom LD Ugeskr Laeger; 2020 Nov; 182(47):. PubMed ID: 33215580 [TBL] [Abstract][Full Text] [Related]
38. Randomized controlled trial of magnesium sulfate in women at risk of preterm delivery-neonatal cardiovascular effects. Paradisis M; Osborn DA; Evans N; Kluckow M J Perinatol; 2012 Sep; 32(9):665-70. PubMed ID: 22094492 [TBL] [Abstract][Full Text] [Related]